# A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer

> **NCT03533127** · PHASE3 · UNKNOWN · sponsor: **Luye Pharma Group Ltd.** · enrollment: 648 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer Recurrent

## Interventions

- **DRUG:** LY01008
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03533127
- **Lead sponsor:** Luye Pharma Group Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-11-27
- **Primary completion:** 2020-06-28
- **Final completion:** 2020-12-28
- **Target enrollment:** 648 (ESTIMATED)
- **Last updated:** 2018-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03533127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03533127, "A Study of LY01008 and Bevacizumab Combined With Paclitaxel and Carboplatin for Treatment of Naïve Subjects With Metastatic or Recurrent Nonsquamous Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03533127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*